|
|
|
|
|
|
|
|
|
|
abstract
INTRODUCTION:
The
estrogen receptor (ER) is expressed at high levels in many epithelial
ovarian cancers (EOC) and represents a potential target for endocrine
therapy. Both anti-estrogens and aromatase inhibitors have been
evaluated in phase II clinical trials.
Areas covered: We present an overview of the phase II and phase III trials of anti-estrogens (tamoxifen and fulvestrant) and aromatase inhibitors (letrozole, anastrazole and exemestane) undertaken in epithelial ovarian cancer identified through a Pubmed search. We describe predictive biomarkers that are being investigated to identify responsive cancers.
Expert commentary:
The efficacy of endocrine therapy in epithelial ovarian cancer is likely to be confined to histological subtypes with the highest ER expression while low grade serous ovarian cancer appears to be one subgroup with good sensitivity to these agents. The low toxicity profile of these agents is favourable although their use is unlicensed and the optimal setting undefined. Prospective clinical trials of endocrine agents in the early relapse and maintenance settings are urgently required to establish their definitive role in the management of epithelial ovarian cancer.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Ovarian Cancer | 2016 ASCO Annual Meeting | Abstracts | Meeting Library
Areas covered: We present an overview of the phase II and phase III trials of anti-estrogens (tamoxifen and fulvestrant) and aromatase inhibitors (letrozole, anastrazole and exemestane) undertaken in epithelial ovarian cancer identified through a Pubmed search. We describe predictive biomarkers that are being investigated to identify responsive cancers.
Expert commentary:
The efficacy of endocrine therapy in epithelial ovarian cancer is likely to be confined to histological subtypes with the highest ER expression while low grade serous ovarian cancer appears to be one subgroup with good sensitivity to these agents. The low toxicity profile of these agents is favourable although their use is unlicensed and the optimal setting undefined. Prospective clinical trials of endocrine agents in the early relapse and maintenance settings are urgently required to establish their definitive role in the management of epithelial ovarian cancer.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Sunday, June 12, 2016 (blog post date)
Ovarian Cancer | 2016 ASCO Annual Meeting | Abstracts | Meeting Library
Ovarian Cancer | 2016 ASCO Annual Meeting | Abstracts | Meeting Library
Ovarian Cancer
Gynecologic Cancer
2016 ASCO Annual Meeting
| ABSTRACT TITLE | FIRST AUTHOR | ABSTRACT NO. |
|---|
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.